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Abstract
Background: Gram-negative bacilli are a cause of serious infections in the pediatric population. Carbapenem are
the treatment of choice for infections caused by multidrug-resistant Gram-negative bacilli, but the emergence of
carbapenem resistance has substantially reduced access to effective antimicrobial regimens. Children are a population
vulnerable to bacterial infections and the emergence of resistance can worsen prognosis. The aim of this study is
to describe the clinical and molecular characteristics of infections caused by carbapenem-resistant Gram-negative
bacilli in pediatric patients from five tertiary-care hospitals in Medellín, Colombia.
Methods: A cross-sectional study was conducted in five tertiary-care hospitals from June 2012 to June 2014. All
pediatric patients infected by carbapenem-resistant Gram-negative bacilli were included. Clinical information for
each patient was obtained from medical records. Molecular analyses included PCR for detection of blaVIM, blaIMP
blaNDM, blaOXA-48 and blaKPC genes and PFGE and MLST for molecular typing.
Results: A total of 59 patients were enrolled, most of them less than 1 year old (40.7 % n = 24), with a previous
history of antibiotic use (94.9 %; n = 56) and healthcare-associated infections - predominately urinary tract infections
(31.0 %; n = 18). Klebsiella pneumoniae was the most frequent bacteria (47.4 %), followed by Enterobacter cloacae
(40.7 %) and Pseudomonas aeruginosa (11.9 %). For K. pneumoniae, KPC was the predominant resistance mechanism
(85.7 %; n = 24) and ST14 was the most common clone (39.3 % n = 11), which included strains closely related by
PFGE. In contrast, E. cloacae and P. aeruginosa were prevailing non-carbapenemase-producing isolates (only KPC
and VIM were detected in 1 and 3 isolates, respectively) and high genetic diversity according to PFGE and MLST
was found in the majority of the cases.
Conclusions: In recent years, increasing carbapenem-resistant bacilli in children has become in a matter of great
concern. It is important to conduct systemic surveillance and take measures to prevent dissemination of multidrug-
resistant bacteria.
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Background
Gram negative bacteria are responsible for a significant
number of infections associated with health care in the
pediatric population, especially Klebsiella pneumoniae,
Escherichia coli and Pseudomonas aeruginosa [1].
The carbapenems are considered the last resort anti-
biotics used for infections caused by multi-resistant
Gram-negative bacilli, due to their stability against
beta-lactamases penicillinases and cephalosporinases,
and their broad spectrum of action [2]. Additionally,
carbapenems are often the only option in the treatment
of severe infections due to the side effects of other anti-
biotics in the pediatric population [1].
In recent years, frequent use of carbapenems has led
to the emergence of resistance mechanisms, mediated
primarily by enzymes called carbapenemases [3, 4].
These enzymes are found in mobile genetic elements
which afford their dissemination and further limit treat-
ment options, because they often harbor mechanisms of
resistance to other antibiotics such as fluoroquinolones
and aminoglycosides, necessitating the use of highly
toxic antibiotics such as colistin [3, 4].
The clinical impact of carbapenem resistance has
become a public health problem around the world in
terms of increased mortality, longer hospital stays, and
higher costs [5]. The child population in this issue is of
great concern as it is a naturally vulnerable population
in which the risk may vary, depending on immuno-
logical maturity, the presence of comorbidities, the
presence of invasive medical devices, and even the prior
use of antibiotics [6, 7].
In Colombia, the rates of carbapenem-resistant
Gram-negative bacilli have increased significantly in
recent years. Klebsiella pneumoniae cabapenemase
(KPC) has been frequently reported in Enterobacteria-
ceae and have started to be reported in Pseudomonas
aeruginosa isolates, leading to KPC being considered
endemic in the country [8, 9]. Additionally, outbreaks
of NDM carbapenemase isolates, often associated with
high levels of resistance to carbapenems and other β-
lactams, have been reported in neonatal intensive care
units [10].
The behavior of infections caused by carbapenem-
resistant bacteria has been studied in adults [11, 12].
However, despite the serious situation, very little is
known about the difference in the behavior of infec-
tions caused by carbapenem-resistant bacteria in the
pediatric population to that of infections reported in
the adult population [1, 13, 14].
The aim of this study, therefore, was to describe the
clinical and molecular characteristics of infections
caused by carbapenem-resistant Gram-negative bacilli in




A cross-sectional study was conducted at five tertiary
care hospitals located in Medellín, Colombia, from June
2012 to June 2014. Hospitals A and E are large university
hospitals of 754 and 700 beds respectively, while hospitals
B and C are medium-size tertiary care institutions (286
and 300 beds respectively), and hospital D is a 140-bed
cardiology hospital. All patients under 15 years old and
infected by carbapenem non-susceptible Pseudomonas
aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae
or Acinetobacter baumannii were included [15]. Micro-
biological and molecular analyses were performed on the
first bacterial isolates recovered during hospitalization.
Clinical and epidemiological data
Both clinical and epidemiological information were
obtained from the medical records of each patient. This
information included sociodemographic characteristics,
antimicrobial use, hospitalization and surgical history,
intensive care unit (ICU) stay, type of infection, comorbid-
ities, treatment and outcomes such as therapeutic failure,
cure, and death. Infections were classified as either com-
munity or healthcare associated, according to standard
epidemiological definitions established by the U.S. Centers
for Disease Control and Prevention (CDC) [16].
Bacterial identification and antibiotic susceptibility
Identification of isolates and their antibiotic suscepti-
bilities were carried out with the Vitek 2 automated
system (BioMérieux, Marcy l’Etoile, France), according
to CLSI [15].
Detection of carbapenemasas and molecular typing
The presence of carbapenemases was evaluated through
PCR amplification of genes blaKPC, blaVIM, blaIMP,
blaNDM and blaOXA-48, using previously described
primers and conditions [17, 18]. After PCR amplifica-
tion, forward and reverse sequencing was performed.
Sequences were compared with those available at Gen-
Bank (www.ncbi.nlm.nih.gov/blast/) and Lahey database
(http://www.lahey.org/Studies/).
Pulse-field gel electrophoresis (PFGE) was performed
using 50 U of SpeI, 20 U of XbaI and 50 U XbaI restric-
tion enzime (Thermo Scientific, United States) for P.
aeruginosa, K. pneumoniae and E. cloacae, respectively.
DNA fragment patterns were normalized using the bac-
teriophage Lambda ladder PFGE marker (New England
Biolabs, UK). Electrophoresis was performed on a CHEF
DR III (Bio-Rad Laboratories, Hercules, CA) at 11 °C,
angle 120° and voltage gradient 6 V/cm. Cluster analysis
was performed using the Dice coefficient in BioNu-
merics software version 6.0 (Applied Maths, Sint-
Martens-Latem, Belgium). Dendrograms were generated
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by the unweighted pair group method using average
linkages (UPGMA), with 1 % tolerance and 0.5 %
optimization settings. A similarity cutoff of ≥80 % was
used to define genetically related strains.
Multilocus sequence typing (MLST) was performed
using the methodology previously described on a sub-
set of isolates representing the most frequent PFGE
patterns in P. aeruginosa and K. pneumoniae [19, 20].
Allele numbers and sequence types (ST) were assigned




Categorical variables were described using absolute and
relative frequencies. Median and interquartile range or
mean and standard deviation were used for continuous
variables, according to data distribution. Statistical
analyses were carried out using the software package
SPSS® v20.0 (SPSS Inc., Chicago, USA).
Results
Clinical and epidemiological characteristics
Of a total about 673 pediatric patients infected by K.
pneumoniae, E. cloacae, P. aeruginosa and A. baumannii
during the study period, 59 (8.8 %) were infected by
carbapenem-resistant isolates and were included in this
report; most of them male (55.9 %; n = 33) and less than
1 year old (40.7 %; n = 24).
Klebsiella pneumoniae was found to be the most fre-
quent cause of infection in the study population (47.4 %,
n = 28), followed by E. cloacae and P. aeruginosa
(40.7 %, n = 24 and 11.9 %, n = 7; respectively). No
patients infected with A. baumannii were observed.
Hospital A contributed the largest number of cases
(40.7 %; n = 24), followed by Hospital B (27.1 %; n = 16)
and Hospital C (18.6 %; n = 11). However, P. aerugi-
nosa was predominant in Hospital A (66.7 %; n = 16),
while K. pneumoniae was more frequent in hospital B
(39.3 % n = 11).
Ninety-seven percent (n = 57) of infections were classi-
fied as health care associated according to CDC criteria
after individual assessment of cases. The most common
infections were urinary tract infections (45.8 %; n = 27),
of which 15.5 % (n = 9) were associated to use of urinary
catheters. At the time of sample collection, 42.4 % (n = 25)
of patients were hospitalized in the intensive care unit
(ICU) and 78 % (n = 46) had had invasive medical device
procedures, such as central venous catheters (n = 29), in-
ternal nutrition probes (n = 28), urinary catheters (n = 20)
and mechanical ventilation (n = 17) (Table 1).
The medical histories of patients revealed the presence
of comorbidities and frequent use of antibiotic within
the past 6 months (94.9 %, n = 56), mainly carbapenems
and piperacillin / tazobactam (37.3 %; n = 22), which
were also those most commonly used as empirical
treatments. Likewise, a high percentage of patients with
history of hospitalization (74.6 %; n = 44) and surgery
during the previous six months (62.7 %; n = 37) were
found, more so in the case of K. pneumoniae than other
bacteria (Table 1).
In the targeted therapy, the use of colistin is highlighted
in the patients infected with K. pneumoniae (50 %; n = 14)
and the use of aminoglycosides and fluoroquinolones of
those infected with P. aeruginosa (25 %: n = 6).
The main outcome in the patients studied was cure
(69.1 %; n = 38), however, all-cause mortality resulted in
16.4 % (n = 9) of cases. The median of hospital stay was
higher for infections caused by K. pneumoniae (48 days)
compared to those caused by P. aeruginosa and E. clo-
acae (33 and 29, respectively) (Table 1).
Antibiotic susceptibility
In K. pneumoniae isolates, high frequencies of ertape-
nem, imipenem and meropenem resistance were ob-
served (94.1, 92, and 89.3 %, respectively). With the
exception of amikacin and ciprofloxacin, the resistance
rate to all antibiotics tested was over 70 %. In contrast,
in P. aeruginosa and E. cloacae isolates, imipenem resist-
ance was observed in 100 % of cases, and for other anti-
biotics, including meropenem and ertapenem, resistance
was under 67 % (Fig. 1).
Carbapenemases detection and molecular typing
The presence of carbapenemases was observed mainly in
isolates of K. pneumoniae, being 85.7 % (n = 24) positive
for KPC carbapenemase, of which 21 contained KPC-2
and 3 KPC-3. For P aeruginosa and E. cloacae, most iso-
lates were non-carbapenemase producing (87.5 %, n = 21
and 85.7 %; n = 6, respectively). Carbapenemase VIM-2
was found in three isolates of P. aeruginosa, and one
isolate of E. cloacae was positive for KPC-3. Most K.
pneumoniae isolates were closely related (Dice coeffi-
cient > 82 %) and MLST revealed isolates belonged to
ST14 (39.3 % n = 11). The isolates of E. cloacae and P.
aeruginosa were highly diverse and the ST170 and
ST1804 were found in P. aeruginosa (Fig. 2).
Discussion
The present study describe clinical and molecular char-
acteristics of infections caused by carbapenem-resistant
Gram-negative bacilli in children and provided an over-
view in order to improve our understanding of the
problem become in a matter of great concern.
In this study, the majority of infections were health-
care associated, which have had a significant worldwide
increase, especially in children [1, 14, 21, 22]. Different
studies have reported the relationship between the
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Table 1 Demographic and clinical characteristics of patients infected by carbapenem resistant Gram-negative bacilli
Characteristic Total Pseudomonas aeruginosa Klebsiella pneumoniae Enterobacter cloacae
No. (%) No. (%) No. (%) No. (%)
Gender
Male 33 (55.9) 16 (66.7) 13 (46.4) 4 (57.1)
Female 26 (44.1) 8 (33.3) 15 (53.6) 3 (42.9)
Age (yrs)
< 1 24 (40.7) 8 (33.3) 12 (42.8) 4 (57.1)
1 a 4 13 (20.0) 6 (25.0) 7 (25.0) 0
5 a 8 13 (20.0) 5 (20.8) 6 (21.4) 2 (28.6)
9 a 12 6 (10.2) 3 (12.5) 2 (7.1) 1 (14.3)
> 12 3 (5.1) 2 (8.3) 1 (3.6) 0
Hospital stay (days) Me (RI) 37 (16–76) 33 (15–70) 48 (25–77) 29 (10–33)
Hospital
A 24 (40.7) 16 (66.7) 5 (17.9) 3 (42.9)
B 16 (27.1) 2 (8.3) 11 (39.3) 3 (42.9)
C 11 (18.6) 3 (12.5) 7 (25.0) 1 (14.3)
D 7 (11.9) 3 (12.5) 4 (14.3) 0
E 1 (1.7) 0 1 (3.6) 0
History in past 6 months
Hospitalization 44 (74.6) 15 (62.5) 25 (89.3) 4 (57.1)
Surgery 37 (62.7) 15 (62.5) 19 (67.9) 3 (42.9)
Stay in ICU 30 (50.8) 13 (54.2) 15 (53.6) 2 (28.6)
Immunosuppressive therapy 16 (27.1) 8 (33.3) 6 (21.4) 2 (28.6)
Dialysis 8 (13.56) 3 (12.5) 5 (17.9) 0
Antimicrobial use in past 56 (94.9) 23 (95.8) 27 (96.4) 6 (85.7)
Carbapenems 22 (37.3) 7 (29.2) 13 (46.4) 2 (28.6)
Piperacillin-tazobactam 22 (37.3) 3 (12.5) 15 (53.6) 4 (57.1)
Glycopeptides 18 (30.5) 7 (29.2) 10 (35.7) 1 (14.3)
1st-generation cephalosporin 17 (28.8) 6 (25.0) 8 (28.6) 3 (42.9)
Aminoglycosides 13 (22.0) 5 (20.8) 8 (28.6) 0
4th-generation cephalosporin 10 (16.9) 3 (12.5) 6 (21.4) 1 (14.3)
Penicillin 9 (15.3) 5 (20.8) 3 (10.7) 1 (14.3)
Fluoroquinolones 9 (15.3) 0 7 (25.0) 2 (28.6)
3rd-generation cephalosporin 8 (13.6) 6 (25.0) 2 (7.1) 0
TMP-SMX 7 (11.9) 2 (8.3) 5 (17.9) 0
Macrolides 2 (3.4) 2 (8.3) 0 0
Lincosamides 2 (3.4) 0 2 (7.1) 0
Oxazolidinones 2 (3.4) 0 2 (7.1) 0
2nd-generation cephalosporin 1 (1.7) 1 (4.2) 0 0
Colistin 1 (1.7) 0 1 (3.6) 0
Monobactams 1 (1.7) 0 1 (3.6) 0
Lipopeptides 1 (1.7) 1 (4.2) 0 0
Infection type
Health care associated 57 (96.6) 23 (95.8) 28 (100) 6 (85.7)
Community associated 2 (3.4) 1 (4.2) 0 1 (14.3)
Vanegas et al. BMC Infectious Diseases  (2016) 16:463 Page 4 of 10
Table 1 Demographic and clinical characteristics of patients infected by carbapenem resistant Gram-negative bacilli (Continued)
Hospitalization in ICU at time of isolate 25 (42.4) 10 (41.7) 12 (42.9) 3 (42.9)
Medical device 46 (78.0) 20 (83.3) 20 (71.4) 6 (85.7)
Central venous catheter 29 (49.2) 12 (50.0) 14 (50.0) 3 (42.9)
Enteral nutrition 28 (47.5) 12 (50.0) 12 (42.9) 4 (57.1)
Urinary catheter 20 (33.9) 6 (25.0) 12 (42.9) 2 (28.6)
Invasive mechanical ventilation 17 (28.8) 9 (37.5) 6 (21.4) 2 (28.6)
Parenteral nutrition 8 (13.6) 3 (12.5) 5 (17.9) 0
Comorbidities 56 (94.9) 22 (91.7) 28 (100.0) 6 (85.7)
Cardiovascular disease 12 (20.3) 4 (16.7) 7 (25.0) 1 (14.3)
Neurologic disease 7 (11.9) 3 (12.5) 3 (10.7) 1 (14.3)
Lung disease 6 (10.2) 3 (12.5) 1 (3.6) 2 (28.6)
Chronic renal disease 5 (8.5) 4 (16.7) 1 (3.6) 0
Transplant 5 (8.5) 2 (8.3) 2 (7.1) 1 (14.3)
Trauma 3 (5.1) 1 (4.2) 2 (7.1) 0
Burns 3 (5.1) 2 (8.3) 1 (3.6) 0
Cancer 2 (3.4) 0 2 (7.1) 0
Leukemia 2 (3.4) 1 (4.2) 1 (3.6) 0
Cystic fibrosis 1 (1.7) 1 (4.2) 0 0
Immunosuppression 1 (1.7) 1 (4.2) 0 0
Infection site
Urinary tract infection (UTI) 18 (31) 5 (20.8) 10 (37.0) 3 (42.9)
Catheter-associated UTI 9 (15.5) 3 (12.5) 6 (22.2) 0
Ventilator-associated pneumonia 7 (12.2) 2 (8.3) 3 (11.1) 2 (28.6)
Bloodstream 6 (10.3) 1 (4.2) 4 (14.8) 1 (14.3)
Pneumonia 6 (10.3) 5 (20.8) 1 (3.7) 0
Catheter-related bloodstream 3 (5.2) 2 (8.3) 1 (3.7) 0
Skin and soft tissue 2 (3.4) 2 (8.3) 0 0
Surgical site 1 (1.7) 0 0 1 (14.3)
Intra-abdominal 1 (1.7) 0 1 (3.7) 0
Empirical therapy 51 (86.4) 19 (79.2) 25 (89.3) 7 (100.0)
Carbapenems 16 (27.1) 4 (16.7) 11 (39.3) 1 (14.3)
Piperacilin-tazobactam 16 (27.1) 7 (29.2) 6 (21.4) 3 (42.9)
Glycopeptides 13 (22) 6 (25.0) 5 (17.9) 2 (28.6)
Aminoglycosides 13 (22) 2 (8.3) 9 (32.1) 2 (28.6)
4th-generation cephalosporin 7 (11.9) 4 (16.7) 1 (3.6) 2 (28.6)
Fluoroquinolones 3 (5.1) 1 (4.2) 2 (7.1) 0
Monobactams 2 (3.4) 2 (8.3) 0 0
3rd-generation cephalosporin 2 (3.4) 2 (8.3) 0 0
1st-generation cephalosporin 1 (1.7) 0 (0) 1 (3.6) 0
Penicillin 1 (1.7) 0 0 1 (14.3)
Oxazolidinones 1 (1.7) 0 1 (3.6) 0
TMP-SMX 1 (1.7) 0 1 (3.6) 0
Colistin 1 (1.7) 0 1 (3.6) 0
Vanegas et al. BMC Infectious Diseases  (2016) 16:463 Page 5 of 10
hospital environment and the presence of infections
caused by resistant bacteria, which has been associated
with mortality rates as high as 37 % in the pediatric
population [1, 14, 23]. These infections particularly
affect children under one year old, a feature that was
observed in this study and that can be explained by the
immunological immaturity of infancy, which leads to
neonatal patients being more susceptible [23–26].
In addition to the aforementioned, other factors that
may facilitate infections by resistant bacteria are prema-
ture birth, low birth weight (associated with increased
mortality), long hospital stays, the use of medical de-
vices, underlying conditions, and previous contact with
the hospital environment. These last three characteris-
tics were frequently found in the patients included in
this study [1, 6, 14].
Of all healthcare-associated infections, urinary tract
infection has been reported as one of the most frequent
both in the pediatric population and in children under
one year old. It was also the most commonly found
infection in this study, though the results contrast with
those reported in other studies in which the most
frequently occurring infections are bacteremia and
pneumonia [1, 23, 25].
The proportion of catheter- associated urinary tract
infections was 15 %, which shows the need to strengthen
hand-hygiene, contact precautions and the replacement
of invasive devices. Many of the outbreaks of infection
caused by Gram-negative bacilli in neonatal and pediatric
units have been the result of failures in these measures
[1, 27]. Additionally, bacteria such as K. pneumoniae y
P. aeruginosa have the ability to form biofilm, allowing
them to adhere to different materials [1, 27].
Although bacteria-resistant infection rates are higher in
ICU compared to other hospital wards, less than half of
the patients in this study were hospitalized in this service,
which shows the importance of epidemiological surveil-
lance of these infections in wards other than ICU [6, 28].
Medical records show prior antibiotics use, predomin-
antly carpabenems, in almost 95 % of patients in this
study, which has been considered an independent risk
factor for infections caused by resistant bacteria in both
adults and children [11, 23, 29, 30]. These findings
highlight the importance of establishing of antimicro-
bial stewardship programs as a strategy to control the
spread of antibiotic-resistant bacteria in the pediatric
population, and more importantly still, in neonatal and
pediatric intensive care units where these medications
are used the most frequently (55.8 %; 95 % CI: 50.3-
61.3 %) [31].
Additionally, the use of antibiotics at an early age not
only encourages the evolution of resistant bacteria, but
also changes the body microbiota, which in turn has
been associated with subsequent infections and even
with immune disorders such as asthma, and metabolic
disorders such as obesity [32]. This in turn heightens
the risk of intestinal colonization by resistant bacteria,
which in neonatal patients encourages the transmission
of these microorganisms to their households after the
hospitalization period [33].
Table 1 Demographic and clinical characteristics of patients infected by carbapenem resistant Gram-negative bacilli (Continued)
Targeted therapy 53 (89.8) 20 (83.3) 27 (96.4) 6 (85.7)
Colistin 16 (27.1) 2 (8.3) 14 (50.0) 0
Aminoglycosides 16 (27.1) 6 (25.0) 9 (32.1) 1 (14.3)
Carbapenems 14 (23.7) 3 (12.5) 10 (35.7) 1 (14.3)
Fluoroquinolones 10 (16.9) 6 (25.0) 3 (10.7) 1 (14.3)
4th-generation cephalosporin 9 (15.3) 5 (20.8) 2 (7.1) 2 (28.6)
Piperacilin-tazobactam 4 (6.8) 3 (12.5) 0 1 (14.3)
Monobactams 2 (3.4) 1 (4.2) 1 (3.6) 0
3rd-generation cephalosporin 2 (3.4) 2 (8.3) 0 0
Glycopeptides 1 (1.7) 0 1 (3.6) 0
Oxazolidinones 1 (1.7) 0 1 (3.6) 0
TMP-SMX 1 (1.7) 0 1 (3.6) 0
Surgical Treatment 6 (10.2) 3 (12.5) 3 (10.7) 0
Outcome
Cure 38 (69.1) 13 (59.1) 20 (76.9) 5 (71.4)
Death 9 (16.4) 4 (18.2) 4 (15.4) 1 (14.3)
Improvement 7 (12.7) 4 (18.2) 2 (7.7) 1 (14.3)
Voluntary discharge 1 (1.8) 1 (4.5) 0 0
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As has been reported in other studies, this investiga-
tion found Klebsiella pneumoniae to be the most
frequently-occurring microorganism [1, 14, 34]. For this
bacteria the resistance mechanism observed in the ma-
jority of outbreaks was KPC, the enzyme encoded on
mobile genetic elements such as transposon Tn4401,
and which has been reported not only in the family En-
terobacteriaceae, but also in non-fermetative bacilli
such as Pseudomonas aeruginosa [8, 35, 36]. These gen-
etic elements may also harbor resistance determinants
to other antibiotics classes, as was evident in the high
resistance rates of K. pneumoniae isolates compared
with P. aeruginosa and E. cloacae, which for the most
part did not contain carbapenemases, and had a higher
sensitivity to aminoglycosides and meropenem [37, 38].
Within the group of aminoglycosides, amikacin sensitivity
was higher than gentamicin sensitivity in isolations of K.
pneumoniae and P. aeruginosa, a previously-observed
characteristic in carbapenem resistant strains found in
children [6].
It has been reported that the presence of carbape-
nemases such as KPC, further restricts the treatment
that can be administered to pediatric patients be-
cause it limits therapeutic options not only within
the beta-lactam groups, but also in other families of
antibiotics [6, 39, 40]. The result has been antimi-
crobials in monotherapy or in combinations for the
treatment of these infections, which can be highly
toxic and can cause serious side effects in still-
growing patients [39, 40].
In this study, 28/59 carbapenem-resistant isolates
were positive for carbapenemases. The remained isolates
negative to these enzymes could harbor other mecha-
nisms for carbapenem resistance, including overex-
pression of efflux systems as MexAB-OprM for P.
aeruginosa, overexpression of AmpC or ESBL betalac-
tamases combined with permeability alteration (defi-
cient expression or loss of porins) in K. pneumoniae,
E. cloacae and P. aeruginosa or other carbapenemases
were not evaluated [41, 42].
Fig. 1 Resistance percentages in carbapenem resistant Gram-negative bacilli
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Another significant finding was the presence of the K.
pneumoniae ST14 clone as the main cause of infections
in the patients of the study. Previous reports have sug-
gested the importance of this clone in the pediatric
population, particularly in infants and have described it
as a high-risk clone, due to its ability to spread and host
resistance determinants to beta-lactams, including ESBL
such as CTX -M-15 and carbapenemases such as KPC
and NDM-1 [43–46].
Although the carbapenem-resistant K. pneumoniae
ST258 clone is more widespread worldwide and has
been found in outbreaks in neonatal units, it was not
found in this study, agreement with previous research in
Italy and Colombia, which a high frequency of non -ST258
clones were described [47, 48]. Meanwhile, the high
genetic variability observed in isolates of P. aeruginosa
and E. cloacae show a high antibiotic pressure that is
conducive to the presence of new clones such as
ST1804, reported for the first time in Colombia [8].
Finally, in this study there was not carbapenem-resistant
Acinetobacter baumannii isolates, which is quite prevalent
is other countries. Recent studies have shown a decrease
in the frequency of resistant A. baumannii isolates in
comparison with other multidrug-resistant Gram-negative
bacilli causing infection in Colombia and particularly
in Medellín [21, 49]. Likewise, a surveillance study
conducted by our research group in five hospitals of
Medellin, included only 32 carbapenem-resistant iso-
lates during two years of study, showing the low fre-
quency of this bacteria in our city [50].
Fig. 2 Genetic relatedness of carbapenem resistant Gram-negative bacilli
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Conclusions
This study demonstrates an increase in the presence of
Gram-negative carbapenem-resistant bacilli in the pediatric
population, which has become a matter of serious concern.
This mainly affects children less than 1 year old with
underlying conditions, prior contact with the hospital
environment, and a history of previous antibiotics use.
It is important to conduct regular monitoring and es-
tablish stewardship programs of antibiotics to prevent
the spread of resistant bacteria, which limit treatment
options in a population particularly vulnerable to these
infections.
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